PAT4 is abundantly expressed in excitatory and inhibitory neurons as well as epithelial cells  by Roshanbin, Sahar et al.
Available online at www.sciencedirect.comwww.elsevier.com/locate/brainres
b r a i n r e s e a r c h 1 5 5 7 ( 2 0 1 4 ) 1 2 – 2 5http://dx.doi.org/10.
0006-8993 & 2014 Th
nCorresponding a
E-mail addresses:
atieh.tafreshiha@gm
Robert.Fredriksson@
Open access under CC BYResearch ReportPAT4 is abundantly expressed in excitatory
and inhibitory neurons as well as epithelial cellsSahar Roshanbin, Sofie V. Hellsten, Atieh Tafreshiha, Yinan Zhu,
Amanda Raine, Robert Fredrikssonn
Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, SE 75124, Swedena r t i c l e i n f o
Article history:Accepted 5 February 2014
PAT4, the fourth member of the SLC36/proton dependent amino acid transporter (PAT)
family, is a high-afﬁnity, low capacity electroneutral transporter of neutral amino acids likeAvailable online 14 February 2014
Keywords:
PAT4
Amino acid transporter
Lysosomal transporter
SLC36
SLC36A4
Brain
In situ hybridization
Immunohistochemistry
Immunoﬂourescence
Mouse1016/j.brainres.2014.02.01
e Authors. Published by
uthor.
Sahar.Roshanbin@neuro
ail.com (A. Tafreshiha),
neuro.uu.se (R. Fredrikss
-NC-ND license.a b s t r a c t
proline and tryptophan. It has also been associated with the function of mTORC1, a
complex in the mammalian target of rapamycin (mTOR) pathway. We performed in situ
hybridization and immunohistological analysis to determine the expression proﬁle of
PAT4, as well as an RT-PCR study on tissue from mice exposed to leucine. We performed a
phylogenetic analysis to determine the evolutionary origin of PAT4. The in situ hybridiza-
tion and the immunohistochemistry on mouse brain sections and hypothalamic cells
showed abundant PAT4 expression in the mouse brain intracellularly in both inhibitory
and excitatory neurons, partially co-localizing with lysosomal markers and epithelial cells
lining the ventricles. Its location in epithelial cells around the ventricles indicates a
transport of substrates across the blood brain barrier. Phylogenetic analysis showed that
PAT4 belongs to an evolutionary old family most likely predating animals, and PAT4 is the
oldest member of that family.
& 2014 The Authors. Published by Elsevier B.V. Open access under  CC BY-NC-ND license.4
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on).1. Introduction
The SLC superfamily is the largest group of transporters and
currently consists of 384 members (Sreedharan et al., 2011)
divided into 52 families (Hediger et al., 2013) with members
belonging to the same family sharing at least 20–25%
sequence homology (Hediger et al., 2004). The range of
solutes transported by these proteins is exceptionally broad,
including nucleotides, neurotransmitters, oligopeptides, drugsand amino acids and yet close to 40% of all SLCs are
still orphan (Fredriksson et al., 2008). Of the 52 families, 11
families include amino acid transporters (Broer and Palacin,
2011; Fredriksson et al., 2008). The mammalian SLC super-
family can be divided into 4 different groups based on their
evolutionary origin; α, β, γ, δ. The β-group is the second largest
group and consists of SLC32, 36 and 38-families and contains
the highest number of amino acid transporters sharing a
common evolutionary origin and similar substrate proﬁle
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is an evolutionary old group, proposed to be homologous with
the ATF-group in plants (Su et al., 2004; Sundberg et al., 2008).
Facilitated transporters and ion-coupled secondary active trans-
porters constitute the SLC superfamily. The coupling of ions
allows for transport against solute concentration gradients,
whilst taking advantage of the electrochemical gradients. In
prokaryotes and lower eukaryotes, Hþ has been the primary
driving force of ion-coupled transport, whereas the vast majority
of transporters in higher eukaryotes exhibit Naþ-coupling or ion-
independence (Saier, 2000).
The SLC36 family consists of four members, PAT1-4, of
which PAT1 and PAT2 are more widely characterized. The
ﬁrst member in the SLC36 family was cloned from cDNA from
rat brain in 2001 (Sagne et al., 2001), characterized as the ﬁrst
rheogenic neuronal lysosomal amino acid transporter and
named LYAAT1. It is localized to GABAergic and glutamater-
gic neurons in mice as well as murine axonal exocysts
(Wreden et al., 2003). This suggested that members from
the SLC36 family could have an important physiological role
in the brain as most other transporters thus far discovered
had been localized to plasma membranes or mitochondria
(Palacin et al., 1998). Upon its identiﬁcation, it was classiﬁed
as belonging to one of the three subfamilies within the amino
acid/auxin permease (AAAP) family, the other two being the
VGAT transporter group, designated the SLC32 family in the
SLC nomenclature (McIntire et al., 1997; Sagne et al., 1997)
and the system A/N transporter group (Saier, 2000; Young
et al., 1999), also known as the SLC38 family (Mackenzie and
Erickson, 2004). The AAAP family was later shown to be a
phylogenetically related and named the β-group in the SLC
classiﬁcation (Wipf et al., 2002; Young et al., 1999). The most
common name for this transporter is however PAT1, as the
identiﬁcation at a molecular level revealed that it was a
proton dependent amino acid transporter. A table of the
nomenclature used for the proteins in the SLC36-family can
be found in a recent review by Thwaites and Anderson
(Thwaites and Anderson, 2011); in this article, we will use
the PAT-nomenclature. PAT1 has a wide substrate proﬁle
including small, unbranched zwitterionic α-, β-, and γ-amino
and imino acids and amino acid derivatives like GABA (Abbot
et al., 2006; Anderson et al., 2004; Boll et al., 2002; Boll et al.,
2003a; Chen et al., 2003a; Sagne et al., 2001) and is ubiqui-
tously expressed but most predominantly in brain, intestine
and kidney. The closely related PAT2 was cloned from
mouse in 2002 (Boll et al., 2002) and has a narrower sub-
strate proﬁle and expression pattern. It is localized in lung,
heart, testis, muscle, kidney, spleen, bone and adipose tissue
(Bermingham and Pennington, 2004; Boll et al., 2002;
Sundberg et al., 2008) as well as in differentiating Schwann
cells (Bermingham et al., 2002). It mainly transports glycine,
alanine and proline, but with a higher afﬁnity for α-amino
acids than PAT1. Mutations in the gene encoding PAT2 has
also been connected to imunoglycinuria, a recessive auto-
somal disease affecting renal transport (Broer et al., 2008).
PAT1 and PAT2 share a similar transport mechanism; both
use an independently established electrochemical gradient of
Hþ to drive substrate translocation and both are bidirectional
(Rubio-Aliaga et al., 2004) as well as exhibiting an ordered
binding proﬁle wherein the proton is bound before thesubstrate. PAT2 however shows a higher proton-afﬁnity than
PAT1, and its substrate afﬁnity is more dependent on pH
(Foltz et al., 2004b). The SLC36 family also contains two
additional transporters, SLC36A3 (PAT3) and SLC36A4
(PAT4). PAT3 is an orphan transporter only found in testis.
The tissue localization of SLC36A3 is known on the mRNA
level (Boll et al., 2003b, 2004), however no protein localization
data is available. PAT4 is the most recently characterized
amino acid transporter in the SLC36-family. It was ﬁrst
identiﬁed as LYAAT-2, in concordance with the then prescribed
nomenclature (Wreden et al., 2003) and was identiﬁed on the
basis of sequence similarity (Boll et al., 2002; Foltz et al., 2004b). It
is ubiquitously expressed in various tissues, (Foltz et al., 2004b;
Nishimura and Naito, 2005; Sundberg et al., 2008) as well as in
several cancer cell lines (Heublein et al., 2010), although its
detailed expression pattern has not been established. The genes
coding for the human PAT1, PAT2 and PAT3 are located on
chromosome 5q33.1 in rather close proximity while the gene
encoding PAT4 is located on chromosome 11q14.3. However, the
evolutionary history and phylogenetic relationship of the SLC36
family is largely unknown.
Recent studies show that PAT4 has a very high afﬁnity for
proline followed by tryptophan, and a lower afﬁnity for
alanine and glycine, resembling the other characterized
PAT-proteins (Pillai and Meredith, 2011). As both proline
and tryptophan are key substrates in neurotransmitter synth-
esis, this suggests that PAT4 could have an important
regulatory role in neuronal transmission. Further, the studies
indicate that the non-acidic pH conditions at which the
transport rate is at its highest, and the apparent electroneu-
tral transport makes PAT4 a non-Hþ-coupled transporter
functioning through facilitated diffusion.
To investigate the role of PAT4 in the nervous system, we
have herein investigated localization and expression of the
transporter in the mouse brain on mRNA- and protein level.
We have shown that Slc36a4 mRNA is widely expressed and
that the protein is found mainly on the soma of neurons. We
found interesting expression in the epithelial cells lining the
ventricles, suggesting that PAT4 could be important in reg-
ulating transport of amino acids into the brain. A qPCR study
with tissue from mice receiving the satiety-inducing amino
acid leucine showed an upregulation of the mRNA expression
in the paraventricular nucleus of the hypothalamus. From a
phylogenetic analysis involving nine different species we con-
clude that PAT4 is the evolutionary oldest protein in the SLC36
family and that PAT1, PAT2 and PAT3 originated from a
common ancestor after the origin of amphibians. PAT4 could
therefore have retained the most original PAT function.2. Results
Widespread Slc36a4 mRNA expression in mouse brain – Non-
radioactive in situ hybridization was used to map the tissue
expression of Slc36a4 mRNA. Floating 70 mm coronal sections
from mouse brain were hybridized with 1 mg digoxigenin
labeled probe against Slc36a4 mRNA. The mRNA expression
was widespread as seen in the overview panel with
annotations in Fig. 1. Marked expression was found in piri-
form cortex (Fig. 1G), hippocampus with particular strong
Fig. 1 – Detailed Slc36a4 mRNA expression in 70 lm coronal WT mouse brain sections. Non-radioactive in situ hybridization
was used for detection of Slc36a4 mRNA using 1 lg digoxigenin-labeled anti-Slc36A4 riboprobe. Expression was seen in
piriform cortex, hippocampus and hypothalamus, in particular in ventromedial preoptic nucleus (VMPO); A, median preoptic
nucleus (MnPO); B, periventricular nucleus (Pe); C, anterior cortical amygdaloid area (ACo); D, medial preoptic nucleus lateral
part (MPOL); E, paraventricular nucleus of the hypothalamus, ventromedial part (PaV); F, piriform cortex (Pir); G,
retrochiasmatic area (RCh); H, paraventricular nucleus (PVN); I, supraoptic nucleus (SO); J, granular layer of the dentate gyrus
(GrDG); K and N, ventromedial hypothalamic nucleus, dorsomedial part (VMHDM); L, arcuate nucleus (Arc); L and M,
dorsomedial hypothalamic nucleus (DM); M, locus coeruleus (LC) and Barrington's nucleus (Bar); O, Bregma coordinates and
abbreviations as referenced by Franklin and Paxinos (2007).
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as hippocampal pyramidal cells (Fig. 1K and N). In the
hypothalamus, staining was revealed in the arcuate nucleus
(Fig. 1L and M), periventricular nucleus (Fig. 1C), paraventri-
cular nucleus (Fig. 1F and I), ventromedial hypothalamic
nucleus (Fig. 1L), dorsomedial hypothalamic nucleus
(Fig. 1M) and in the retrochiasmatic area (Fig. 1H). Further-
more, Slc36a4 mRNA was detected in the supraoptic nucleus
(Fig. 1J), lateral part of medial preoptic nucleus (Fig. 1E),
ventromedial preoptic nucleus (Fig. 1A), medial preoptic
nucleus lateral part (Fig. 1B), cortical amygdaloid area
(Fig. 1D) as well as locus coeruleus and Barrington's nucleus
(Fig. 1O).
Verifying the speciﬁcity of the PAT4 antibody – Combined
in situ hybridization and immunohistochemistry was used
to investigate co-localization of Slc36a4 mRNA with the PAT4Fig. 2 – Western Blot and combined in situ hybridization and im
mouse brain revealed a strong band at approximately 65–70 kDa
P1 fraction. For deﬁnition of S1 and P1, see Section 4. The comb
showed an overlap, here seen in (I) retrosplenial dysgranular co
gyrus (GrDG and MoDG, respectively), (III) medial posterior and l
respectively) and (IV) posteriomedial cortical nucleus of the hypo
and Paxinos (2007).protein to verify the speciﬁcity of the antibody, along with a
Western Blot analysis, both shown in Fig. 2. The in situ
hybridization was performed using the riboprobe mentioned
previously and the ﬂuorescent immunohistochemistry using
a monospeciﬁc polyclonal anti-PAT4 antibody with a recom-
binant epitope signature tag, PrEST. The Western Blot analy-
sis showed a single band approximately at 65–70 kDA, slightly
larger than the predicted protein size of 56.2 kDa (Fig. 2A).
This larger size could be due to posttranslational modiﬁca-
tions; this is highly possible as the sequence contains ﬁve
strong N-glycosylation sites, as predicted by the NetNGlyc
server (http://www.cbs.dtu.dk/services/NetNGlyc/). In addi
tion, the combined in situ hybridization and immunohisto
chemistry revealed an overlap between the mRNA and the
PAT4-protein, thus further verifying the speciﬁcity of the
antibody (Fig. 2B).munohistochemistry. (A) Western Blot on fractionated WT
in the S1 fraction and a weaker band of the same size in the
ined in situ hybridization and immunohistochemistry (B)
rtex (RSD), (II) granular and molecular layer of the dentate
ateroposterior part of the arcuate nucleus (ArcMP and ArcLP,
thalamus (PMCo). Abbreviations as referenced to by Franklin
b r a i n r e s e a r c h 1 5 5 7 ( 2 0 1 4 ) 1 2 – 2 516PAT4 is expressed in neurons and epithelial cells – Double
immunohistochemistry with ﬂuorescent markers on WT
parafﬁn sections was used for determination of cell-speciﬁcexpression of PAT4. A high degree of co-localization of PAT4
with the neuronal marker NeuN (Mullen et al., 1992) was
found in cortex, indicating expression of PAT4 on the
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rons (Fig. 3D). The latter was also conﬁrmed through co-
staining with glutamic acid decarboxylase 67 protein (GAD67),
a marker for inhibitory GABAergic neurons (Kaufman et al.,
1991) showing a co-expression of PAT4 and GAD67 in some
but not all PAT4-expressing cells in cortex (Fig. 3A). We
observed no overlap between PAT4 and MAP2, a marker for
neuronal microtubule-associated protein 2 (Bernhardt and
Matus, 1984), suggesting that PAT4 is not found in neuronal
axons (Fig. 3C). Staining with the whole-neuron marker
speciﬁc to axons, dendrites, nuclei and soma of neurons,
the Pan neuronal cocktail (Doyle et al., 2010) (Fig. 3E) and
PAT4 also shows expression of PAT4 mainly in neuronal cell
bodies. Overlap with the two aforementioned markers indi-
cates that PAT4 is predominantly expressed in the soma,
with no overlapping expression in neuronal ﬁbers. There was
no co-expression of PAT4 and synaptophysin (Fig. 3G), a
marker of pre-synaptic vesicles (Wiedenmann and Franke,
1985) suggesting that PAT4 is not present at synapses. There
was no overlap in expression between PAT4 and the astro-
cytic marker glial ﬁbrillary acidic protein (GFAP) (Reeves et al.,
1989) (Fig. 3B); however, there was a high degree of overlap
between PAT4 and pan-Cytokeratin, an epithelial marker
(von Overbeck et al., 1985), around the lateral ventricles
(Fig. 3F), showing expression of PAT4 in epithelial cells.
PAT4 displays intracellular expression – Triple immunohisto-
chemistry on immortalized hypothalamic cells was performed
to study the subcellular localization of PAT4, using the PAT4-
antibody along with the membrane marker WGA and the
lysosomal markers Cathepsin-D and LAMP2, respectively. The
lack of co-localization of PAT4 and WGA suggests that PAT4 is
not expressed on the plasma membrane but rather intracellu-
larly, seen in Fig. 4A and C. The channel intensities along the
white arrows in Fig. 4A and C are depicted in the adjacent
graphs, respectively (Fig. 4B and D), showing that peaks from
the WGA staining do not co-localize with peaks from the
PAT4- and the lysosomal staining, suggesting that PAT4 is
expressed intracellularly. The staining in the images along
with the graphs also show a partial co-localization of PAT4 and
the lysosomal markers LAMP2 and Cathepsin-D.
High PAT4 expression in hippocampus, hypothalamus and piri-
form cortex – The expression of PAT4 in 70 mm coronal sectionsFig. 3 – Cellular localization of PAT4 to neurons and epithelial cel
on WT parafﬁn sections was used to determine the cellular loca
monospeciﬁc polyclonal PAT4 antibody, and all markers used w
DAPI, seen in blue. (A) Co-localization with GAD67; most neuron
inhibitory neurons are also stained with PAT4 in cortex, but not
in both inhibitory and excitatory neurons. (B) Co-localization wit
marker GFAP in cortex. (C) Co-localization with MAP2; the overla
and PAT4 in cortex in the merged image indicates an expression
the merged image shows a high degree of co-localization of PA
PAT4 is expressed in most neurons, both inhibitory and excitat
expression of PAT4 in cortex with the whole neuron marker Pa
soma of neurons indicate that PAT4 is expression is conﬁned to
the merged image depicting he overlap between PAT4 and the e
suggests that PAT4 is expressed in epithelia. (G) Co-localization
synaptophysin, a marker for pre-synaptic vesicles.of mouse brain was investigated through immunohistochem-
istry with DAB, using the PAT4-antibody, as shown in Fig. 5.
The expression pattern follows that of the in situ hybridiza-
tion with a high degree of staining in the pyramidal cells (Pyr)
and the molecular and granular layers of the dentate gyrus in
the hippocampus (PoDG and GrDG, respectively) (Fig. 5E), in
the arcuate nucleus (Arc) and the dorsomedial hypothalamic
nucleus (DMH) (Fig. 5D) and piriform cortex (Fig. 5C). High
levels of expression are also found in the suprachiasmatic
nucleus (SCh) and the horizontal limb of the diagonal band
(HDB), the periventricular nucleus (Pe), the bed nucleus of the
stria terminalis (STMPI) (Fig. 5A) as well as in the retro-
chiasmatic area (RCh). Other areas with interesting staining
in the hypothalamus include; ventromedial hypothalamic
nucleus (VMH) and the peduncular part of lateral hypothala-
mus (PLH) (Fig. 5B). Further, strong staining is seen in the
basomedial amygdala (BMA) and the central amygdaloid
nucleus (Ce). The lateral division of the mamillary nucleus
(ML), substantia nigra (SN), ventral tegmental area (VTA) and
the interfascicular nucleus (IF) (Fig. 5F) also exhibited strong
staining, accompanied by the medial accessory oculomotor
nucleus (MA3) and the interpeduncular nucleus rostral
subnucleus (IPR).
PAT4 is the evolutionary oldest member of the SLC36-family –
To investigate the evolutionary history of the SLC36 family
we constructed a phylogenetic tree based on all SLC36 like
sequences from nine different species (Fig. 6A). We also
included the complete set of SLC32 and SLC38 family
proteins from human. Here we show that the SLC36, SLC32
and SLC38 sequences form three separate basal branches in
the phylogeny. The analysis also suggests that there was a
single SLC36 gene before the split of Trichoplax adhaerens and
that this gene was duplicated before the teleost ﬁsh lineage.
Interestingly, the PAT1, 2 and 3 were formed from a common
ancestor after the split of amphibians. PAT1, 2 and 3 are
located on chromosome 5q33.1 next to each other, covering
a genomic are of less than 250,000 bases. Also these genes
have highly similar exon–intron organization, all consisting
of 10–11 coding exons which taken together suggests that
they were formed by a recent local duplication of genomic
material. We propose an evolutionary scheme for how the
SLC36 family was formed (Fig. 6B).ls – Double immunohistochemistry with ﬂuorescent markers
lization of PAT4. PAT 4 was stained in red using the
ere stained in green. The cell nuclei have been stained with
s stained with GAD67, a GABAergic marker for most
the other way around. This indicates that PAT4 is expressed
h GFAP; there is no overlap between PAT4 and the astrocytic
pping expression of the neuronal microtubule marker MAP2
of PAT4 in the neuronal soma. (D) Co-localization with NeuN;
T4 and the neuronal marker NeuN in cortex, indicating that
ory. (E) Co-localization with Pan neuronal cocktail; the co-
n neuronal cocktail aimed at axons, dendrites, nuclei and
the neuronal soma. (F) Co-localization with pan-Cytokeratin;
pithelial marker pan-Cytokeratin around the lateral ventricle
with synaptophysin; there is no overlap between PAT4 and
Fig. 4 – Intracellular localization of PAT4. Triple immunohistochemistry with ﬂuorescent markers on hypothalamic cells was
used to investigate the subcellular localization of PAT4 as well as the overlap with the lysosomal markers LAMP2 and
Cathepsin D. Confocal images of the cells were analyzed using the LSM 510 software, with the channel intensities along the
arrows in the merged images depicted in the graphs. PAT4 was stained in violet, WGA in red, DAPI in blue and the markers
LAMP2 and Cathepsin-D in green. The confocal images of the immunohistochemistry show a partial co-localization of PAT4
and LAMP2 (A) and Cathepsin-D (B) and the respective graphs showing the different channel intensities show no co-
localization between PAT4 and WGA, the membrane marker (see arrows in the graphs).
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We have previously shown that PAT4 is expressed in many
tissues in rat using quantitative realtime PCR (Sundberg et al.,
2008). Here, we show using in situ hybridization that Slc36a4
mRNA is abundantly expressed also in mouse brain, predo-
minantly in piriform cortex, hippocampus and hypo-
thalamus. We also performed the ﬁrst immunohistological
analysis of PAT4 showing a high abundance in mouse brain
similar to the mRNA expression. We used ﬂuorescent double
immunohistochemistry to show that PAT4 is localized mainly
in the soma of both inhibitory and excitatory neurons, but
not in any astrocytes or glia cells. Fluorescent triple immu-
nohistocheimstry on hypothalamic cells show an apparent
intracellular localization of PAT4 with a partial overlap with
lysosomal markers. The polyclonal antibody used here also
shows some staining in the nucleus. It is possible that this
staining is unspeciﬁc at the concentrations used as it is
unlikely that an amino acid transporter has a physiological
function in the nucleus. We have chosen to treat the nuclear
staining with caution and do not discuss this further here.
We performed a phylogenetic analysis (Fig. 6A) that showed
that members from the SLC36 family were present already in
the placozoan T. adhaerens, which is a sister group to the
bilaterian group containing most animals. This shows that
the SLC36 family is evolutionary old and most likely predates
animals. Interestingly, PAT4 appears to be the evolutionary
oldest member, and the previously studied members, PAT1,
PAT2 and PAT3 originated from a common ancestral gene
within the tetrapod lineage. The clustering and closerevolutionary relationship of PAT1-3 suggests that there are
two subfamilies within the SLC36 family, the PAT1-3 sub-
family and PAT4 subfamily. Data also suggests that these
subfamilies are distinct not only in evolutionary terms, but
also functionally. The two subfamilies differ in regards to
expression pattern and substrate proﬁle as well as mode of
transport, making the functional characterization of PAT4 of
interest. The transport mechanism exerted so far by the
previous members PAT1 and PAT2 is a proton-dependent;
in where an ordered binding of a proton followed by sub-
sequent translocation of both proton and substrate across the
membrane in which it is located. It has been shown that
various factors can affect the transport rate and the substrate
afﬁnity, in particular pH and membrane potential to different
degrees. It has also been shown that transport of certain
substrates, mainly short-chain fatty acid-derivatives, by
PAT1- and PAT2 is electroneutral rather than rheogenic
(Foltz et al., 2004a). When the transport mechanism of PAT4
was investigated, a similar theory arose; the apparent elec-
troneutrality of the transport taken together with the basic
pH giving the best transport rate suggested that this trans-
porter not be proton-dependent, in contrast to PAT1
and PAT2.
Substrate analysis has found proline to be the main
substrate of PAT4, followed by tryptophan. Considering the
interchangeable qualities of proline, glutamate and gluta-
mine and the expression of other proline-speciﬁc transpor-
ters in rat brain in glutamatergic neuronal subpopulations,
the transport of proline into these areas has been suggested
to play a role in excitatory neurotransmission (Johnson and
Roberts, 1984). The metabolism of proline in brain is further
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are associated with, suggesting proline to have an important
role in brain function and development. PAT1 is also known
to transport proline, as well as alanine, which is also involved
in excitatory neurotransmission (Westergaard et al., 1993).
Although these amino acids can both be synthesized in glial
cells, neither PAT1 nor PAT4 are expressed in glial cells.
However, considering the expression of PAT4 in both excitatory
and inhibitory neurons, the role of PAT4 in these neurons cannot
be conﬁned to glutamatergic neurotransmission. Another high-
afﬁnity substrate of PAT4 is the aromatic, essential amino acid
tryptophan. Tryptophan is metabolized into serotonin, an inhi-
bitory neurotransmitter (Hamon et al., 1979).
We show that PAT4 is mainly found on the cell bodies of
neurons, with a staining pattern surrounding the cell
nuclei, while PAT1 have been shown to be expressed in
the lysosomes as well as in the plasma membrane (Wreden
et al., 2003). This is supported also by the fact that PAT1 and
PAT2 transport is dependent on the Hþ gradient, a feature
common for transporters expressed in internal membranes
such as lysosomes (Chen et al., 2003b) and synaptic vesi-
cles. The overlaps of PAT4 with the epithelial cell marker
pan-Cytokeratin around the ventricles in the brain indicate
that PAT4 is involved in transporting substrates from the
cerebrospinal ﬂuid across the choroid plexi. This is in line
with previous ﬁndings of proline and neutral amino acid
transport across choroid plexus, albeit with a low afﬁnity
(Ross and Wright, 1984). The ﬁndings in the described
immunolocalization studies also point to a possible differ-
ential subcellular expression of PAT4, previously exhibited
by other transporters (Geerlings et al., 2002; Soontornmalai
et al., 2006).
To summarize, we have performed a detailed analysis of
Slc36a4 mRNA distribution in mouse brain, and an immu-
nohistological analysis mapping the protein expression in
mouse brain, both showing an abundant expression in
piriform cortex, hippocampus and hypothalamus. Fluores-
cent immunohistochemistry revealed intracellular localiza-
tion of PAT4 in inhibitory and excitatory neurons. PAT4 is
also present in epithelial cells lining the ventricles in the
brain, suggesting that it is involved in transporting neutral
amino acids like proline from the blood. Phylogenetic ana-
lysis shows that SLC36-family is evolutionary old, and that
PAT4 is the oldest member, differing in both chromosome
location and transport mechanism from the other charac-
terized members. RT-PCR on brain tissue from mice receiv-
ing leucine in diet showed an upregulation of Slc36a4 mRNA
in the PVN, in line with the ﬁnding that leucine is an
activator of mTOR, along with recent studies showing that
PAT4 together with PAT1 is required for mTORC1 activation.4. Experimental procedures
4.1. Ethics statement
Animal care procedures for C57Bl6/J adult male mice were
approved by the local ethical committee in Uppsala and
followed the guidelines of European Communities Council
Directive (86/609/EEC).4.2. Tissue preparation
Animal care procedures for C57Bl6/J adult male mice were
approved by the local ethical committee in Uppsala and
followed the guidelines of European Communities Council
Directive (86/609/EEC). Adult male C57Bl6/J mice (Taconic
M&B, Denmark) were intraperitoneally injected with
400 mg/kg sodium pentobarbital (APL, Sweden) and transcar-
dially perfused with phosphate buffered saline (PBS) followed
by 4% formaldehyde. (Histolab, Sweden). Immediately follow-
ing the perfusion, the brains were removed and immersed in
the same ﬁxative at 4 1C overnight. The brains were then
transferred to 2% formaldehyde and kept there until section-
ing. Free ﬂoating tissue sections were acquired by washing
the brains with PBS (25) followed by embedding in 4%
agarose (Pronadisa Conda, Spain) and sectioning (70 mm) on a
Leica VT1000S vibratome (Leica Microsystems, Germany).
Free ﬂoating sections for immunohistochemistry were kept
in PBS at 4 1C after sectioning, whereas sections for in situ
were dehydrated with successive methanol washes and
stored in 100% methanol at 20 1C. For parafﬁn-embedded
tissue sections, the brain was ﬁxed in zinc-formalin (Richard-
Allan Scientiﬁc) for 18–24 h at 40 1C before dehydration and
parafﬁn infusion (Tissue-Tek vacuum inﬁltration processor;
Miles Scientiﬁc). The sections were cut (7 μm) using a Microm
355S STS cool cut microtome (Thermo Fisher Scientiﬁc,
Germany) attached on Superfrost Plus slides (Menzel-Gläser,
Germany), dried overnight at 37 1C, and stored at 4 1C
until use.
4.3. In situ hybridization on free ﬂoating sections
Free ﬂoating sections were rehydrated by successive 10 min
washes in methanol and phosphate buffered saline with 0.1%
Tween-20 (Sigma–Aldrich, Sweden), PBT. The sections were
then bleached in 6% hydrogen peroxide for 15 min, followed
by washes in PBT before incubation in 0.5% Triton X-100
(Sigma–Aldrich, Sweden) for 5 min. After additional washes
in PBT, the sections were digested with 20 mg/mL proteinase K
(Invitrogen, Sweden) for 3 min and the digestion was stopped
using PBT. The sections were postﬁxated in 4% formaldehyde
(HistoLab, Sweden) for 35min before a 2 h pre-incubation in
hybridization buffer (50% formamide (Sigma–Aldrich, Sweden)
5 SSC, 1% SDS, 50 mg/mL tRNA (Sigma–Aldrich, Sweden),
50 mg/mL heparin (Sigma–Aldrich, Sweden) in PBT) at 55 1C. The
Slc36a4 probe (1 mg/mL) diluted in hybridization buffer was heat-
denatured at 80 1C for 5min, cooled on ice and added to the
sections for overnight hybridization at 55 1C. Unbound probe was
washed off by sequential 330min washes in buffer 1 (50%
formamide, 2 SSC, 0.1% Tween-20) and buffer 2 (50% forma-
mide, 0.2 SSC, 0.1% Tween-20) at 55 1C. The sections were
washed in 0.1% Tween-20 in Tris-buffered saline (TBST) for
25min with subsequent incubation in 1% blocking reagent
(Roche Diagnostics Scandinavia, Sweden) for 2 h. The blocking
was followed by incubation in the anti-digoxigenin antibody
conjugated to alkaline phosphatase (Roche Diagnostics Scandi-
navia, Sweden)) diluted 1:5000 in blocking solution overnight at
4 1C. Unbound antibody was washed off with 510min washes
with TBST with 2 mM levamisole (Thermo Fischer Scientiﬁc,
USA), followed by incubation in NTMT with 2 mM levamisole
b r a i n r e s e a r c h 1 5 5 7 ( 2 0 1 4 ) 1 2 – 2 520(100 mM NaCl, 10mM Tris HCl, pH 9.5, 50mM MgCl2, 0.1%
Tween-20) for 10min before color development with BM-Purple
AP enzyme substrate (Roche Diagnostics Scandinavia, Sweden)at 37 1C. After mounting in 50% glycerol and TBST, the sections
were scanned with Mirax Pannoramic Scanner (3dHistech,
Hungary). For in situ hybridizations all solutions were made with
b r a i n r e s e a r c h 1 5 5 7 ( 2 0 1 4 ) 1 2 – 2 5 21diethylpyrocarbonate (DEPC)-treated ddH2O to ensure absence of
RNAses.4.4. Double in situ/immunohistochemistry on parafﬁn
sections
The parafﬁn sections were deparafﬁnized in X-Solve (210
min) (Meditek histotechnik, Germany) and rehydrated
through 2 min washes in graded ethanol to PBS, followed by
washes in PBS (22 min). The sections were postﬁxated in
4% formaldehyde (Histolab, Sweden) for 10 min in room
temperature and digested with proteinase K (Invitrogen,
USA) for 15 min. The sections were then reﬁxated in the
same ﬁxative for 5 min at room temperature, washed in PBS
(25 min) and acetylated with 1.3% triethanolamine Sigma–
Aldrich, Sweden), 0.06 HCl (Sigma–Aldrich, Sweden), 2% acetic
anhydride (Fluka, Switzerland) in DEPC for 10 min. Following
this, sections were treated with 1% Triton X-100 (30 min)
with subsequent washes in PBS (35 min) prior to pre-
hybridization in hybridization buffer 50% formamide (Sigma–
Aldrich, Sweden), 5 SSC, pH 4.5, 5 Denhardt's, 250 μg/mL
of yeast transfer RNA (Sigma–Aldrich, Sweden), sheared
salmon sperm DNA (500 μg/mL Ambion) in 0.1% diethyl
pyrocarbonate-treated water) for 2 h at 55 1C. The sections
were then hybridized at 55 1C with heat denatured Slc36a4
probe (0.7 mg/mL) at 55 1C overnight. Unbound probe was
removed with washes in pre-warmed 5 SSC at 55 1C,
followed by incubation in 0.2 SSC for 1 h at 55 1C, and
subsequent washes in 0.2 SSC (25 min) at room tempera-
ture. Thereafter, the sections were pre-blocked in blocking
solution (0.1 M Tris HCl, pH 7.5, 0.15 M NaCl, and 10%
albumin bovine serum (Sigma-Aldrich, Sweden) for 1 h. The
sections were incubated in alkaline phosphatase-conjugated
anti-digoxigenin Fab fragments (Roche Diagnostics Scandina-
via, Sweden) diluted 1:2500 and primary antibody anti-PAT4
(1:200) in blocking solution at 41 overnight. Following the
incubation, the sections were washed with TBST with 2 mM
levamisole and NTMT with 2 mM levamisole as previously
described. The sections were developed in Fast Red Solution
(Roche Diagnostics Scandinavia, Sweden) followed by washes
in PBS (35 min) and incubation in secondary donkey anti-
rabbit-488 antibody (Invitrogen, Sweden) for 1 h. Following
washes in PBS (35 min), the sections were incubated in the
cell nucleus marker, 40,6-diamidino-2-phenylindole (DAPI,
1:1250, Sigma–Aldrich, Sweden) diluted in blocking solution
for 5 min. The sections were washed in PBS (35 min) and
mounted with DTG antifade mounting medium (2.5% DABCOFig. 5 – High PAT4 expression in hippocampus, hypothalamus a
used for tissue mapping of PAT4 in 70 lm ﬂoating coronal secti
appertaining magniﬁed images. Strong expression was seen in (
of the diagonal band (HDB), periventricular nucleus (Pe), bed nu
(RCh) peduncular part of lateral hypothalamus (PLH), (C) piriform
nucleus (Ce), (D) arcuate nucleus (Arc), ventromedial hypothalam
(E) cortex, the hippocampal pyramidal cells, fasciola cinereum (F
dentate gyrus (PoDG), lateral division of mamillary nucleus (ML)
nigra compact (SNC), substanita nigra lateral (SNL), ventral tegm
(PBP), medial accessory oculomotor nucleus (MA3), interfascicul
(IPR). Bregma coordinates and abbreviations as referenced by Fr(Sigma–Aldrich, Sweden), 50 mM Tris, pH 8.6, 90% glycerol)
and photographed using a ﬂuorescent microscope (Zeiss
Axioplan2 imaging) connected to a camera (AxioCam HRm)
with the Carl Zeiss AxioVision version 4.7 software.
4.5. Fluorescent immunohistochemistry on parafﬁn
sections
The sections were deparafﬁnized and rehydrated as pre-
viously described and. The sections were heated to 100 1C in
0.01 M citric acid pH 6.0 (10 min) (Sigma–Aldrich, Sweden)
and then washed in PBS (35 min), placed in a humidiﬁed
chamber and incubated with primary rabbit anti-PAT4 (1:200,
Sigma–Aldrich, Sweden) mouse anti-NeuN (1:400, Millipore,
Sweden), chicken anti-GFAP (1:400, Abcam, United Kingdom),
mouse anti-MAP2 (1:500, Sigma), mouse anti-synaptophysin
(1:200, BD Transduction Laboratories), mouse anti-pan-
Cytokeratin (1:400, Sigma Aldrich, Sweden), mouse anti-pan
neuronal marker (1:100, Millipore, Sweden), mouse anti-
Gad67 (1:200, Millipore, Sweden) diluted in supermix (Tris-
buffered saline, 0.25% gelatin, 0.5% Triton X-100) overnight at
4 1C. The PAT4 antibody was a rabbit polyclonal antibody
raised against the sequence REELDMDVMRPLINEQNFDGTS-
DEEHEQELLPVQKHYQLDDQEGISFVQTLMHLLKGNIGTGL in the
human PAT4. This sequence is 85% identical in mouse PAT4
and less than 40% conserved in the other PAT family
members. Unbound antibodies were washed off with PBS
(35 min), followed by incubation in 1:400 diluted secondary
antibodies donkey anti-rabbit-594, donkey anti-rabbit-488,
goat anti-mouse-594, goat anti-mouse-488, and goat anti-
chicken-488 (all Invitrogen, Sweden) in supermix for 3 h.
The sections were subsequently washed in PBS (14 min)
and stained with DAPI (1:1250) for 5 min prior to mounting
using DTG and photographed as previously described.
4.6. Fluorescent immunohistochemistry on hypothalamic
cells
Immortalized embryonic mouse hypothalamus cell line
N25/2 (mHypoE-N25/2, Cellutions Biosystems Inc., Canada)
was cultured for 40 h on glass slides previously coated with
10 mg/mL poly-L-lycine. Cells were rinsed with PBS before
ﬁxation in 4% paraformaldehyde (Sigma–Aldrich, Sweden) for
15 min. Slides were blocked in supermix (0.25% gelatin and
0.5% Triton X-100 in TBS) for 1 h at room temperature before
incubation in primary antibodies; the ﬂuorescently labeled
membrane marker wheat germ agglutinin (WGA, 2 mg/mL,nd piriform cortex – Immunohistochemistry with DAB was
on of WT mouse brain. (A)–(F) are overview pictures with
A) suprachiasmatic area (SCh), nucleus of the horizontal limb
cleus of the stria terminalis (STMPI), (B) retrochiasmatic area
cortex (Pir), basomedial amygdala (BMA), central amygdaloid
ic nucleus (VMH), dorsomedial hypothalamic nucleus (DMH),
C), granular layer of the dentate gyrus (GrDG), polymorphic
, (F) substantia nigra compact dors tier (SNCD), substantia
ental area (VTA), parabrachial pigmented nucleus of the VTA
ar nucleus (IF), interpeduncular nucleus rostral subnucleus
anklin and Paxinos (2007).
Fig. 6 – (A) Phylogenetic tree showing the evolutionary relationship between SLC32, SLC36 and SLC38 families as well as the
evolutionary history of the SLC36 family. The tree was constructed using MrBayes 3.2 (Huelsenbeck and Ronquist, 2001; Ronquist
and Huelsenbeck, 2003), and drawn with branchlengths representing evolutionary distance. The numbers at the nodes represents
posterion probability (pp) values, all nodes with a pp value of 1.00 was marked with a black circle. The different subtypes within the
SLC36 family are drawn in separate colors. Species abbreviations: md (Monodelpih domestica), oa (Ornithorhynchus anatinus), me
(Macropus eugenii), mm (Musmusculus), hs (Homo sapiens), bt (Bos taurus), la (Loxodonta africana), tn (Tetraodon nigroviridis), dr (Danio rerio),
xt (Xenopus tropicalis), gg (Gallus gallus), dn (Dasypus novemcinctus), dm (Drosophila melanogaster), ta (Trichoplax adhaerens), nv
(Nematostella vectensis). (B) Proposed evolutionary scheme for how the SLC36 family was formed.
b r a i n r e s e a r c h 1 5 5 7 ( 2 0 1 4 ) 1 2 – 2 5 23Invitrogen, Sweden) rat anti-LAMP2 (1:100, Abcam, United
Kingdom), goat anti-cathepsin-D (1:100, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), and rabbit anti-PAT4 (1:100,
Sigma Aldrich, Sweden) overnight at 4 1C. The following day,
slides were rinsed in PBS 310 min, incubated in secondary
antibodies diluted in supermix; goat anti-rabbit-633, goat
anti-rat-488 and donkey anti-goat-488, (1:400, all Invitrogen,
Sweden) for 1 h at room temperature. Slides were washed in
PBS 210 min, incubated in DAPI (1:1250 in PBS) for 5 min in
room temperature and rinsed 25 min before they were
mounted in DTG. Images were collected on a Zeiss LSM 510
Meta confocal microscope (Carl Zeiss Inc., Thornwood, NY)
and analysis of images was performed using the LSM
Software.
4.7. Non-ﬂuorescent immunohistochemistry on free
ﬂoating sections
Free ﬂoating sections were rinsed in Tris-buffered saline
(TBS) for 410 min before and after incubation in 3% hydro-
gen peroxide/10% methanol in TBS for 20 min. The sections
were pre-blocked in 1% blocking reagent (Roche Diagnostics,
Scandinavia, Sweden) diluted in TBS for an hour and there-
after incubated in rabbit anti-PAT4 (1:1500) diluted in super-
mix (0.25% gelatin and 0.5% Triton X-100 in TBS) overnight at
4 1C. The sections were further rinsed in TBS for 510 min
and incubated in biotinylated secondary goat-anti rabbit
antibody (1:400) diluted in supermix, and rinsed in TBS before
incubation in avidin–biotin complex (1:800; Vectastain ABC
kit, Vector Laboratories, USA) diluted in supermix. The
peroxidase was visualized in black with 0.05% 3,30-diamino-
benzidine tetrahydrochloride (DAB), 0.35% NiCl and 0.01%
H2O2 after 10 min incubation. Sections were mounted on
gelatin-coated slides (Menzel-Gläser, Germany), air-dried
overnight, dehydrated in ascending concentrations of etha-
nol, soaked in xylene, and mounted in DPX (Sigma–Aldrich,
USA). The analysis was performed using a Pannoramic midi
scanner as previously described.
4.8. Western Blot
Western Blot analysis was performed on brain tissue from
one adult, male C57Bl6/J wild type mouse (Taconic M&B,
Denmark). Crude protein extraction was performed by homo-
genizing 0.2 mg brain tissue with equal amount of glass beads
in 1 mL of lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl,
4 mM MgCl, 0.5 mM EDTA, 2% Triton X-100 and 1 mM Pro-
tease inhibitor PMSF diluted in isopropanol (Sigma–Aldrich,
USA)) with a Bullet blender (Next Advance, USA). A short
centrifugation was then performed and the supernatant was
transferred to a new tube. Subsequently, the homogenate
was centrifuged at 1000 g for 10 min, receiving pellet 1 (P1)
and supernatant 1 (S1), with the supernatant transferred
followed by a new centrifugation at 13,000 g for 15 min,
receiving pellets 2 (P2) and supernatant 2 (S2). Protein con-
centrations were determined by protein assay DC according
to manufacturer's instructions (Bio-Rad Laboratories, USA).
The protein concentration was determined using protein
assay DC (Bio-Rad, Hercules, USA). The protein lysate (50 mg
and 200 mg) was separated with gel electrophoresis togetherwith PageRuler prestained protein ladder (Fermentas,
Canada) on a Mini-Protean TGX Precast gel (4–15%, Bio-Rad,
Hercules, USA) in running buffer (0.1% SDS, 0.025 Tris base
and 0.192 M glycine). The proteins were transferred to a
Immobilon-P polyvinylidine ﬂuoride (PVDF) membrane (Milli-
pore, Billerica, USA) in transfer buffer (0.025 Tris base,
0.192 M glycine and 20% methanol) and pre-blocked for 1 h
in blocking buffer (5% non-fat dry milk (Bio-Rad, Hercules,
USA) diluted in 1.5 M NaCl, 0.1 M Tris, 0.05% Tween-20, pH
8.0). The membrane was hybridized with the diluted primary
rabbit-anti-PAT4 (1:50, Sigma Aldrich, Sweden) overnight at
4 1C. The membrane was washed with TBST four times
(11 min and 310 min) and incubated for 1 h with horse-
radish peroxidase conjugated goat anti-rabbit secondary anti-
body (diluted 1:10,000, Invitrogen, USA). This was followed by
detection with the enhanced chemiluminescent (ECL)
method and subsequent washes with TBST as previously
described. The membrane was incubated for 3 min in a 1:1
mixture of luminol/enhancer and peroxidase buffer solution
(Immun-Star HRP, Bio-Rad, USA) and developed on High
performance chemiluminescence ﬁlm (GE healthcare, USA).
4.9. RNA-probe synthesis
Mouse Slc36a4 EST clone ID IRCLp5011G0824D was used to
synthesize the antisense probe. Plasmid cDNA was prepared
with the JETstar 2.0 Plasmid Puriﬁcation Mini Kit/50
(Genomed, Germany), the concentration was measured using
a NanoDrop ND-1000 spectrophotometer (NanoDrop Tech-
nologies), and the clone was sequenced (Euroﬁns MWG
Operon, Germany) and veriﬁed correct. The plasmid was cut
with PstI (Fermentas, Latvia), and the probe was synthesized
using 1 μg of cleaved vector as template with SP6 RNA
polymerase in the presence of digoxigenin-11-UTP (Roche
Diagnostics Scandinavia, Sweden). The digoxigenin-labeled
mouse Slc36a4 probe was then quantiﬁed and controlled for
integrity using the Experion RNA StdSens Analysis kit on an
Experion automated electrophoresis system (Bio-Rad) and
stored at 80 1C.
4.10. Phylogenetic analysis
The complete protein sequence datasets nine different gen-
omes were mined using a Hidden Markov Model (HMM)
trained on the human SLC36 family sequences. The
sequences were ﬁltered against a complete set of human
SLC sequences, to remove false positive hits. The sequences
were aligned using the E-INS_I version of MAFFT (Katoh et al.,
2002) The alignment was manually edited and trimmed using
Jalview (v. 2.6.1) (Waterhouse et al., 2009) to contain only the
transmembrane regions. Incomplete sequences were
removed. Thereafter, a phylogenetic tree was constructed
using the Bayesian approach as implemented in MrBayes
(Huelsenbeck and Ronquist, 2001; Ronquist and Huelsenbeck,
2003). The posterior probabilities were approximated using
Markov Chain Monte Carlo (MCMC) analysis with a model
allowing rate variation across sites under the invariate
gamma distribution. The mixed amino acid model was used
to estimate the optimal evolutionary model. The analysis was
set to run for 5,000,000 generations and a stop rule was used
b r a i n r e s e a r c h 1 5 5 7 ( 2 0 1 4 ) 1 2 – 2 524to terminate the analysis when the split frequencies were
o0.01 and 1% of the trees were sampled. The ﬁrst 25% of the
trees were discarded and the remaining 75% of the trees were
used to calculate a 50% majority rule consensus tree. The
phylogenetic tree was drawn in TreeView (p. 1999) as an
unrooted tree and edited in Canvas 12.
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